Last updated: July 9, 2026
ecutive summary
Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc., No. 1:06-cv-00774 (D. Del.), is a generic-drug patent dispute brought by Reliant against Par. The case record shows a filing in 2006 in the District of Delaware under a patent/infringement framework tied to ANDA market entry, with Reliant as plaintiff and Par as defendant. The litigation’s operative claim scope and the patents asserted are not provided in the information available here, so no accurate claim-by-claim infringement, construction, damages exposure, or settlement terms can be stated.
Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc. | 1:06-cv-00774 litigation summary and analysis
Answer (what happened): A 2006 patent infringement action filed by Reliant Pharmaceuticals Inc. against Par Pharmaceuticals Inc. in the District of Delaware (case number 1:06-cv-00774) to block or address generic market entry.
Answer (who sued whom): Reliant Pharmaceuticals Inc. (plaintiff) v. Par Pharmaceuticals Inc. (defendant).
What court and case number governs Reliant v. Par 1:06-cv-00774?
- Court: U.S. District Court, District of Delaware
- Case number: 1:06-cv-00774
- Year filed: 2006
- Parties: Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc.
Is 1:06-cv-00774 an ANDA Paragraph IV case?
The case caption and typical Delaware venue for brand versus generic patent disputes are consistent with an ANDA-era infringement framework. However, the specific procedural posture (e.g., whether it includes a Paragraph IV certification tied to an ANDA) is not stated in the provided information, so the exact exclusivity and FDA-trigger facts cannot be confirmed.
What patents does Reliant accuse Par of infringing in 1:06-cv-00774?
No patent numbers, publication identifiers, or asserted claims are provided in the available input. Without the asserted patent list and claim set, a legally grounded infringement and validity analysis cannot be produced.
Which patent estate is at issue: composition, method-of-use, or formulation?
Not specified in the available input. Without the asserted patents, you cannot map the dispute to:
- formulation patents (e.g., polymorph, particle size, coating, sustained release),
- method-of-use patents (indication or dosing regimen),
- or composition-of-matter patents (active ingredient or combination).
How does the litigation timeline in 1:06-cv-00774 affect exclusivity and generic entry risk?
A reliable timeline (complaint date, claim construction scheduling, summary judgment, trial dates, and any post-judgment dates) is not included in the provided information. Without docket dates and outcomes, exclusivity and launch-risk sequencing cannot be quantified.
What are the key docket milestones to extract from PACER for 1:06-cv-00774?
Not available here.
What is the procedural posture and what motions were decided in Reliant v. Par?
The available information does not include:
- Rule 12/summary judgment outcomes,
- claim construction rulings,
- preliminary injunction activity,
- or stipulations of dismissal.
Without the rulings, any analysis of claim scope, infringement likelihood, or noninfringement/invalidity defenses would be speculative.
How did the court construe claims in 1:06-cv-00774, and what impact does it have on infringement?
No claim construction order, Markman decision, or asserted-claim chart is provided. Without constructions and the patent claim language, you cannot analyze:
- whether the accused Par product reads on each limitation,
- whether constructions narrow or broaden “material” limitations,
- or whether claim terms are decisive for design-around strategies.
Did Reliant and Par reach a settlement, and what terms control market entry?
Settlement terms (if any) are not included. Without a settlement agreement, you cannot state:
- launch dates,
- covenants not to sue,
- payment obligations,
- exclusivity designations,
- or stipulations affecting FDA submissions and timing.
What is the final judgment status for 1:06-cv-00774?
The case outcome (dismissal, summary judgment, consent judgment, judgment after trial, or settlement with dismissal) is not provided. Without the disposition, you cannot assess:
- ongoing infringement exposure,
- appellate risk,
- or enforcement posture.
How does this case influence the broader patent landscape for Par and Reliant products?
A landscape analysis requires:
- the asserted patents and their remaining life,
- prosecution histories affecting interpretation,
- and whether other parallel cases exist.
None of this information is included here, so the landscape effect cannot be assessed in a way that is actionable.
What generic entry risks exist for Par or other filers based on Reliant v. Par 1:06-cv-00774?
Generic entry risks depend on:
- whether the patents were found invalid or not infringed,
- the effect of any injunction or settlement,
- and whether other related patents remain enforceable.
The required facts are not available in the input.
How strong is Reliant’s patent estate as reflected by 1:06-cv-00774?
Patent strength analysis needs:
- asserted claims and outcomes,
- validity defenses and results,
- and enforcement results.
No asserted-patent or decision data is provided, so patent strength cannot be quantified.
How does this litigation compare with other Reliant vs. Par cases in Delaware?
No related dockets or comparative case outcomes are provided.
Key Takeaways
- The litigation is identified as Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc., No. 1:06-cv-00774, filed in the District of Delaware in 2006.
- Based on the provided information alone, the actionable details required for a business-grade patent litigation analysis (asserted patents, claim constructions, rulings, settlement terms, and final disposition) are not available.
- Any attempt to infer infringement/validity strength, launch timing impact, or market-entry leverage would be unsupported.
FAQs
- Is Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc., 1:06-cv-00774 a Paragraph IV ANDA case?
- Which specific patents were asserted in 1:06-cv-00774 and what claims were at issue?
- Did the court issue an injunction or entry stay in Reliant v. Par 1:06-cv-00774?
- What was the final case disposition and did it occur via settlement or adjudication?
- How would the outcome of 1:06-cv-00774 affect FDA approval timing for Par’s ANDA?
References
- PACER/Case docket: Reliant Pharmaceuticals Inc. v. Par Pharmaceuticals Inc., No. 1:06-cv-00774 (D. Del.).
